Cosmetic cross-reference

Andrographolide

CAS 5508-58-7

Andrographolide (CAS 5508-58-7) is a Phase 3 pharmaceutical compound with 6 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Andrographolide

CAS Number

5508-58-7

UNII

410105JHGR

InChIKey

BOJKULTULYSRAS-OTESTREVSA-N

ChEMBL ID

CHEMBL186141

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL186141 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 6 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	25065.855384615385 nM	87	-
-	Potency	26818.495454545457 nM	19	-
-	GI50	7359.333333333333 nM	15	-
-	EC50	23371.444444444445 nM	9	-
-	MIC	124.5 ug.mL-1	8	-
-	IC50	9.708571428571428 ug.mL-1	7	-

SOURCE IUPHAR/BPS 3 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
TAS2R46 TAS2R46	Agonist	4.889999866485596 pEC50	26406243
TAS2R50 TAS2R50	Agonist	4.639999866485596 pEC50	19817411
TAS2R8 TAS2R8	Agonist	3.9600000381469727 pEC50	32330040

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Andrographolide used for in pharmaceutical contexts?

Andrographolide (CAS 5508-58-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Andrographolide?

No adverse-event association or SIDER side-effect rows are rendered for Andrographolide in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Andrographolide also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Andrographolide with EU status "permitted".

What clinical phase is Andrographolide in?

Andrographolide is rendered with ChEMBL max phase 3.